Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Follow-up Safety and Efficacy Study in Participants With Duchenne Muscular Dystrophy Who Have Received Fordadistrogene Movaparvovec in a Preceding Clinical Study

NCT05689164 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05689164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05689164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Follow-up Safety and Efficacy Study in Participants With Duchenne Muscular Dystrophy Who Have Received Fordadistrogene Movaparvovec in a Preceding Clinical Study
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
March 13, 2023
Completion date
September 24, 2025
Enrollment
7 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy